Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 December 2019 | Story Dr Cindé Greyling | Photo Anja Aucamp
Patents
Dr Mariana Erasmus, SAENSE Platform Manager, says water remediation is vital for both the ecosystem and industries.

KovsieInnovation at the UFS supports innovative research outputs in various ways – one of which is to protect the intellectual property and to register patents where viable. This is in line with KovsieInnovation’s broader aim to create third-stream income for the university. Patent registration is a complex process and the UFS is proud to have the needed expertise to properly facilitate such an endeavour.

The SAENSE Platform

South Africa is a water-scarce country, with many water hungry industries (such as agriculture and mining). “Industrial processes often contaminate water with heavy metals, harmful chemicals, radioactive waste, and even organic sludge,” Dr Mariana Erasmus, SAENSE Platform Manager, explains.

Hence, water remediation is vital for both the ecosystem and industries. One of the key functions of the SAENSE Platform is to offer water-remedial solutions for the (bio)remediation of nitrates, heavy metals, and salts, among others. The platform’s activities and services are supported by undergraduate and postgraduate students and researchers, using Technology Innovation Agency (TIA) funding. TIA is a national public entity that serves as key institutional intervention to bridge the innovation chasm between research and development.

From waste to water

Through the joint effort of two mining companies and the UFS/TIA SAENSE Research Platform, a new treatment for mine drainage (MD) has been developed. This patented B-DAS (Barium – Dispersed Alkaline Substrate) technology effectively treats the major contaminants found in acid, alkaline, or neutral mining wastewater. The aim of the B-DAS system is to provide a passive water-treatment solution with minimum waste production; it can also be a potential pre-treatment for reverse osmosis (RO) to lower the requirements of the membranes and therefore potentially reduce the RO cost.

The success of the patent is that it turns unusable water into water that is fit for agricultural purposes at a reduced cost and increased efficiency.

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept